In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: Implications on hematological malignancies

Leukemia Research

Volumn 30, Issue 9, 2006, Pages 1151-1158

  Galski, Hanan ^a   Sivan, Hamutal ^a   Lazarovici, Philip ^b   Nagler, Arnon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

CML BC; KT 5720; Lymphoma; MDR1; Multiple myeloma (MM); P glycoprotein (Pgp)

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN; GLYCOPROTEIN P; K 252A; K 252B; KT 5720; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLAST CELL CRISIS; CANCER CELL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CARBAZOLES; CELL LINE, TUMOR; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; INDOLES; LEUKEMIA, MYELOID, CHRONIC; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MULTIPLE MYELOMA; P-GLYCOPROTEIN; PYRROLES;

EID: 33745836868     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.02.016     Document Type: Article

References (39)

1. Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol 10 6 (1999) 53-59
2. Sonneveld. Multidrug resistance in haematological malignancies. J Intern Med 247 (2000) 521-534
3. Tulpule A., Sherrod A., Dharmapala D., Young L.L., Espina B.M., Sanchez M.N., et al. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res 26 (2002) 121-127
4. Goldstein L.J., Galski H., Fojo A., Goldstein L.J., Galski H., Fojo A., et al. Expression of a multidrug resistance gene in human cancer. J Natl Cancer Inst 81 (1989) 116-124
5. Leighton J.C., and Goldstein L.J. P-glycoprotein in adult solid tumors. Expression and prognostic significance. Hematol Oncol Clin North Am 9 (1995) 251-273
6. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39 (1999) 361-398
7. Thomas J., Wang L., Clark R.E., and Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104 (2004) 3739-3745
8. Knight G.W., and McLellan D. Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia. Br J Biomed Sci 61 (2004) 103-111
9. Illmer T., Schaich M., Platzbecker U., Freiberg-Richter J., Oelschlagel U., von Bonin M., et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatement with imatinib mesylate. Leukemia 18 (2004) 401-408
10. Woods G., Lund L.A., Naik M., Ling V., and Ochi A. Resistance of multidrug-resistant lines to natural killer-like cell mediated cytotoxicity. FASEB J 2 (1988) 2791-2796
11. N'cho M., Hobbs J.A., and Brahmi Z. Over-expression of multidrug resistance P-glycoprotein inhibits NK granule-mediated lytic ability without affecting the Fas lytic pathway. Hum Immunol 60 (1999) 223-230
12. Kolb H.J., Simoes B., and Schmid C. Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. Curr Opin Oncol 16 (2004) 167-173
13. Shimoni A., and Nagler A. Non-myeloablative stem cell transplantation: lessons from the first decade of clinical experience. Curr Hematol Rep 3 (2004) 242-248
14. Ford J.M. Experimental reversal of P-glycoprotein mediated multidrug resistance by pharmacological chemosensitizers. Eur J Cancer A 32 (1996) 991-1001
15. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 1 (2000) 85-99
16. Friedenberg W.R., Tallman M.S., Brodsky I., Paietta E., Rowe J.M., Lee S.J., et al. Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group. Leuk Res 28 (2004) 813-819
17. Oza A.M. Clinical development of P glycoprotein modulators in oncology. Novartis Found Symp 243 (2002) 103-115
18. Thomas H., and Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10 (2003) 159-165
19. Ross D.D. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol 17 (2004) 641-651
20. Sandler A., Gordon M., De Alwis D.P., Pouliquen I., Green L., Marder P., et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with DOX in patients with advanced malignancy. Clin Cancer Res 10 (2004) 3265-3272
21. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61 (2001) 749-758
22. van Zuylen L., Sparreboom A., van der Gaast A., Nooter K., Eskens F.A., Brouwer E., et al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 38 (2002) 1090-1099
23. Kuppens I.E., Bosch T.M., van Maanen M.J., Rosing H., Fitzpatrick A., Beijnen J.H., et al. Oral bioavailability of docetaxel in combination withOC144-093 (ONT-093). Cancer Chemother Pharmacol 55 (2005) 72-78
24. Stein W.D. Reversers of the multidrug resistance transporter P-glycoprotein. Curr Opin Investig Drugs 3 (2002) 812-817
25. Dietel M., Herzig I., Reymann A., Brandt I., Schaefer B., Bunge A., et al. Secondary combined resistance to the multidrug resistance reversing activity of cyclosporin A in the cell, line F4-6RADR-CsA. J Cancer Res Clin Oncol 120 (1994) 263-271
26. Abbaszadegan M.R., Cress A.E., Futscher B.W., Bellamy W.T., and Dalton W.S. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res 56 (1996) 5435-5442
27. Bhat U.G., Winter M.A., Pearce H.L., and Beck W.T. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of MDR1 and P-glycoprotein in a human colon carcinoma cell line. Mol Pharmacol 48 (1995) 682-689
28. Galski H., Lazarovici P., Gottesman M.M., Murakata C., Matsuda Y., and Hochman J. KT-5720 reverses multidrug resistance in variant S49 mouse lymphoma cells transduced with the human MDR1 cDNA and in human multidrug resistant carcinoma cells. Eur J Cancer 31 (1995) 380-388
29. Lazarovici P., Galski H., Matsuda Y., and Hochman J. KT-5720, a new bacterial alkaloid antibiotic, reverses multidrug resistance (MDR) in lymphoma and carcinoma cells overexpressing MDR1 gene. J Nat Tox 6 (1997) 19-33
30. Findling-Kagan S., Sivan H., Ostrovsky O., Nagler A., and Galski H. Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1. Leuk Res 29 (2005) 407-414
31. Galski H., Bar I., Shemtov N., and Nagler A. Differential inhibition of Pgp (MDR1)-dependent activity in target and effector cells: a new approach to increase graft versus tumor (GVT) effects and tumor sensitivity to adoptive immunotherapy. Exp Hematol 32 (2004) 50 [Abstract 634]
32. Pastan I., Gottesman M.M., Ueda K., Lovelace E., Rutherford A.V., and Willingham M.C. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85 (1998) 4486-4490
33. Bates S.E., Lee J.-S., Dickstein B., Spolyar M., and Fojo A.T. Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry 32 (1993) 9156-9164
34. Galski H., Sullivan M., Willingham M.C., Chin K.V., Gottesman M.M., Pastan I., et al. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia. Mol Cell Biol 9 (1989) 4357-4363
35. Mickisch G.H., Merlino G.T., Galski H., Gottesman M.M., and Pastan I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 88 (1991) 547-551
36. Galski H., Merlino G.T., Gottesman M.M., and Pastan I. Expression of a human multidrug-resistance cDNA (MDR1) under the control of a beta-actin promoter in transgenic mice. Biotechnology 16 (1991) 103-124
37. Mickisch G.H., Licht T., Merlino G.T., Gottesman M.M., and Pastan I. Chemotherapy and chemosensitization of transgenic mice, which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res 51 (1991) 5417-5424
38. Richardson D.S., and Johnson S.A. Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Rev 11 (1997) 201-223
39. Mahadevan D., and List A.F. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 104 (2004) 1940-1951